Trials / Completed
CompletedNCT03593954
A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants
An Open-Label, Fixed-Sequence Study in Healthy Subjects to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the effect of ritonavir, on the single-dose pharmacokinetics (PK) of JNJ-61393215 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-61393215 | Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension. |
| DRUG | Ritonavir | Participants will receive 100 mg of ritonavir tablet orally. |
Timeline
- Start date
- 2018-07-31
- Primary completion
- 2018-09-19
- Completion
- 2018-09-19
- First posted
- 2018-07-20
- Last updated
- 2025-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03593954. Inclusion in this directory is not an endorsement.